Benziodarone is a coronary dilatator drug. Benziodarone in therapeutic dosage has no effect on blood coagulation and does not alter the prothrombin level. Bleeding complications occurred, when benziodarone is given to patients receiving anticoagulant therapy with warfarin sodium. Jaundice might occurred from 8 to 16 weeks after the beginning of the treatment with Benziodarone. Combination of Flecainide with Benziodarone should be avoided or used only with strict monitoring. Benzbromarone is an other benzofuran derivative acting as anuricosuric agent by reducing the proximal tubular reabsorption of uric acid. The hypouricaemic action of benziodarone (Amplivex-Labaz) is prompt. The maximum drop of uricaemia after Amplivex administration (2 tablets/day) occurs during the first three days. The uric acid level declines by as much as 80% of the baseline value. For long-term treatment 1 tablet per day is sufficient, in some instances even 1 tablet twice a week. The tolerance of the preparation is satisfactory.